Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 1/2 3Phase 2 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 31Gynecologic 4Gastrointestinal 4Head & Neck 3Breast 2Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 220Head and Neck Neoplasms 172Carcinoma, Non-Small-Cell Lung 104Melanoma 63Neoplasms 56Colorectal Neoplasms 55Uterine Cervical Neoplasms 53Ovarian Neoplasms 50Stomach Neoplasms 48Neoplasm Metastasis 46Breast Neoplasms 46Triple Negative Breast Neoplasms 45Lung Neoplasms 44Carcinoma, Renal Cell 40Esophageal Neoplasms 37Nasopharyngeal Carcinoma 33Endometrial Neoplasms 33Pancreatic Neoplasms 32Thyroid Neoplasms 30Prostatic Neoplasms 26Carcinoma, Squamous Cell 26Sarcoma 25Colonic Neoplasms 24Urinary Bladder Neoplasms 23Small Cell Lung Carcinoma 23Oropharyngeal Neoplasms 23Carcinoma, Transitional Cell 23Carcinoma 22Salivary Gland Neoplasms 20Nasopharyngeal Neoplasms 20

Interventions

bemarituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Adenocarcinoma of Lung × Head & Neck × Clear all
NCT05325866 2026-02-04

FORTITUDE-301

Amgen

Phase 1/2 Completed
260 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT07341737 2026-01-15

SL-28 for Advanced Solid Tumours

Second Life Therapeutics

Phase 1/2 Not yet recruiting
60 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04161391 2024-06-13

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Turning Point Therapeutics, Inc.

Phase 1/2 Terminated
41 enrolled 18 charts
Head & NeckThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡